# Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

> **NCT01694277** · PHASE3 · COMPLETED · sponsor: **AB Science** · enrollment: 258 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Masitinib
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT01694277
- **Lead sponsor:** AB Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01694277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01694277, "Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01694277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*